Pinnacle Wealth Planning Services Inc. Trims Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Pinnacle Wealth Planning Services Inc. trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 48.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,710 shares of the biotechnology company’s stock after selling 12,034 shares during the period. Pinnacle Wealth Planning Services Inc.’s holdings in BioCryst Pharmaceuticals were worth $96,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 2.7% during the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after purchasing an additional 127,708 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in BioCryst Pharmaceuticals by 16.9% in the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock valued at $25,369,000 after acquiring an additional 481,359 shares during the period. Two Sigma Advisers LP increased its position in BioCryst Pharmaceuticals by 13.6% in the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock worth $16,576,000 after buying an additional 261,500 shares in the last quarter. FMR LLC increased its position in BioCryst Pharmaceuticals by 2.4% in the third quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company’s stock worth $15,112,000 after buying an additional 46,110 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in BioCryst Pharmaceuticals by 4.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock worth $14,890,000 after buying an additional 91,998 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $7.69 on Friday. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -12.61 and a beta of 1.85. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $9.50. The business has a 50 day simple moving average of $8.15 and a 200-day simple moving average of $7.87.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. BioCryst Pharmaceuticals’s revenue was up 40.8% on a year-over-year basis. During the same period last year, the firm earned $0.28 earnings per share. As a group, analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the company. JMP Securities restated a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Royal Bank of Canada reiterated an “outperform” rating and set a $11.00 target price (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Wedbush assumed coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Finally, Evercore ISI increased their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $15.57.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.